(AGENPARL) - Roma, 23 Gennaio 2025 - (AGENPARL) – gio 23 gennaio 2025 Lund, Sweden, January 23, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm:
HNSA), will publish its year-end report for January-December 2024 on February 6,
2025. Interested parties may join the Company’s quarterly conference call on the
same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren Tulstrup,
President and CEO, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call
will include a review of the interim results and a business and pipeline update.
It will be held in English.
Slides used in the presentation will be made available on the company website at
the following link: Financial
reports (https://www.hansabiopharma.com/investors/financial-reports/).
To participate in the telephone conference, please use the dial-in details
provided below:
Participant Toll Free Dial-in: 1-833-821-3542
International Dial-in: 1-412-652-1248
The webcast will be available on
https://event.choruscall.com/mediaframe/webcast.html?webcastid=8Ylnk0T5 (https://
eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fevent.choruscall.com%2F
mediaframe%2Fwebcast.html%3Fwebcastid%3D8Ylnk0T5&data=05%7C02%7Cfilippo.guizzetti
nRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7
C%7C%7C&sdata=ymsevBpdLyQGUxXyeleFAe8bAxEPBWflw%2FW5yAhggA8%3D&reserved=0)
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a second-generation IgG cleaving molecule
with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has
operations in Europe and the U.S. The company is listed on Nasdaq Stockholm
under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3R3EisE2EXCZbmAz7tP1ubM2Q7q7oaq62rWQHLJAdSey2H3e6BLkvj5ShxyxeUbi911jbLhY9WcwtNDu2w3rjwGq5ZXCM2qGxqrqpCEHeHBmmn.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3R3EisE2EXCZbmAz7tP1ubM2Q7q7oaq62rWQHLJAdSey2H3e6BLkvj5ShxyxeUbi911jbLhY9WcwtNDu2w3rjwGq5ZXCM2qGxqrqpCEHeHBmmn.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Comunicato Stampa 2025/2026 Sociale. Costituito l’Ats di Legnago. Assessore Roma “25 Comuni fanno squadra per il sociale
- Iran, la missione all’ONU respinge le accuse sul presunto piano di attentato a Washington
- Orti sociali di via di Salviano, nuovo bando per gli over 65
- RETURN HUB IN RUANDA, TARQUINIO (S&D): COSÌ L’EUROPA DEPORTA ANCHE LE PROPRIE RESPONSABILIT?
- FONDI CIPESS, MARCHETTI (LEGA): “OLTRE 132 MILIONI PER INVESTIMENTI STRATEGICI, SVILUPPO E SICUREZZA DEL TERRITORIO”
- Scuola. Di Maggio (Fdi), con Fdi sconti sui libri. Vediamo chi sta con le famiglie e chi no
- Rifondazione: Come si prova a capovolgere la storia
- NATO, gli Stati Uniti preparano il riequilibrio militare in Europa. Revisione attesa entro il 1° dicembre
- Agenzia nr. 2159 – “Metroquadrato”, il teatro entra nella Casa circondariale di Taranto: due appuntamenti per raccontare un laboratorio finanziato dal Garante regionale
- LEGA, DOMANI VISITA ISTITUZIONALE AL CENTRO DI MONASTIR. A SEGUIRE PUNTO STAMPA